Bristol-Myers Squibb(US:BMY) Schaeffers Investment Research·2026-03-20 13:39Core Viewpoint - Bristol-Myers Squibb Co (NYSE:BMY) is highlighted as a top investment pick for 2026, with potential benefits from capital reallocating towards cash-generative equities if interest rates remain low or stable [1][2]. Financial Performance and Projections - The company is expected to benefit from a rotation in the market that began at the end of 2025, as it has shown strong free cash flow yield and sustainable dividends [2]. - BMY has reclaimed its 200-month moving average and a long-term trendline connecting higher highs from 2004 to 2012, indicating a positive technical outlook [2]. Price Targets - The shares of BMY could test their March 2025 highs of $63, representing nearly an 18% upside from the current levels [3]. - If the stock continues to rise without being capped by this peak, there is potential for a 40% upside towards its former long-term high of $75 within the next 12 months [3].